Document is current

Any future updates will be listed below

Avelumab plus Axitinib: Neuer Standard in der Erstlinie beim fortgeschrittenen Nierenzellkarzinom

Crossref DOI link: https://doi.org/10.1007/s15015-020-2452-9

Published Online: 2020-06-30

Published Print: 2020-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark